Cara Therapeutics Inc. (NASDAQ: CARA) shares made a solid gain on Wednesday after the firm announced that it has licensed rights to commercialize Korsuva (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in dialysis patients.
Previously, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Korsuva injection for this indication, for which there are currently no approved therapies in the United States or European Union.
Cara licensed the worldwide rights, except in the United States, Japan and South Korea, to Vifor Fresenius Medical Care Renal Pharma, which specializes in treatments for chronic kidney disease.
Under the terms of the agreement, Cara will receive an upfront payment in the amount of $50 million in cash and an equity investment of $20 million to acquire Cara common stock at a price of roughly $17 per share. Cara also will�be eligible to receive additional payments of up to $470 million, which includes $30 million in regulatory and up to $440 million in tiered commercial milestones that are all sales related.
Top Medical Stocks To Buy For 2018: Enphase Energy, Inc.(ENPH)Advisors' Opinion:
- [By ]
This direct current (DC) optimized inverter system maximizes power generation at the individual PV module level while lowering the cost of energy produced by the solar PV system. SolarEdge's patented inverter is not only best in class, but also contains an energy storage unit and/or charger, which differentiates it from its main competitor, Enphase energy (Nasdaq: ENPH).
- [By Money Morning News Team]
(Nasdaq: CNET)$2.95 34.76% Seadrill Ltd. (NYSE: SDRL) $0.28 33.81% Intelsat Corp. (NYSE: I) $9.11 31.50% Navios Maritime Midstream Partners LP (NYE: NAP) $4.42 29.18% Limelight Networks Inc. (Nasdaq: LLNW) $4.89 28.61% Enphase Energy Inc. (Nasdaq: ENPH) $5.05 24.62%
As you can see in the table above, penny stocks have the potential to provide tremendous returns for enterprising investors. However, it's important to note that investing in penny stocks is also incredibly risky.
- [By Dan Caplinger]
Even with volatility returning to the market, some investors have been fortunate to find the companies that have been able to enjoy success early in the year. In particular, Fossil Group (NASDAQ:FOSL), Axon Enterprise (NASDAQ:AAXN), and Enphase Energy (NASDAQ:ENPH) have gained more than 100% so far in 2018, and some investors think they have further to climb.
Top Medical Stocks To Buy For 2018: Collegium Pharmaceutical, Inc.(COLL)Advisors' Opinion:
- [By Logan Wallace]
Collegium Pharmaceutical (NASDAQ:COLL) – Piper Jaffray lowered their FY2021 EPS estimates for shares of Collegium Pharmaceutical in a note issued to investors on Wednesday, May 9th. Piper Jaffray analyst D. Amsellem now forecasts that the specialty pharmaceutical company will post earnings per share of $2.06 for the year, down from their previous forecast of $2.32. Piper Jaffray has a “Buy” rating and a $33.00 price target on the stock.
- [By Todd Campbell]
Depomed is in the middle of a restructuring of its business that includes out-licensing its lead drug, Nucynta. In December, Collegium (NASDAQ:COLL) cut a licensing deal for Nucynta that guarantees Depomed $135 million in annual royalties, paid quarterly in arrears, for four years. If sales exceed�$233 million per year, then Collegium Pharmaceutical will also pay Depomed a double-digit royalty on top of the minimum license fee. After four years, Depomed will receive double-digit royalties on all net Nucynta sales.
Top Medical Stocks To Buy For 2018: PulteGroup, Inc.(PHM)Advisors' Opinion:
- [By ]
Higher rates can hurt stocks of companies like homebuilders, which rely on affordable mortgage rates for their customers. "Nobody trusts the homebuilders past the day they report because the litany is always: 'This is the last good quarter when it comes to Lennar (LEN) , Toll Brothers (TOL) , D.R. Horton (DHI) , Taylor Morrison (TMHC) and PulteGroup (PHM) .'"
- [By Peter Graham]
A long term performance chart shows KB Home along with large caps D.R. Horton, Inc (NYSE: DHI), Lennar Corporation (NYSE: LEN) and PulteGroup, Inc (NYSE: PHM) somewhat all taking off once Donald Trump was sworn in:�
- [By Max Byerly]
PulteGroup (NYSE:PHM) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
Top Medical Stocks To Buy For 2018: Express-1 Expedited Solutions Inc.(XPO)Advisors' Opinion:
- [By ]
For his final "Executive Decision" segment, Cramer also checked in with Brad Jacobs, chairman and CEO of XPO Logistics (XPO) , the transportation provider with shares up 16% in 2018.
- [By Steve Symington, Jeremy Bowman, and Demitrios Kalogeropoulos]
So we asked that question to three top Motley Fool investors. Read on to learn why they put New Relic (NYSE:NEWR), XPO Logistics (NYSE:XPO), and Ebay (NASDAQ:EBAY)�on their short lists of stocks capable of outperforming a five-bagger.
- [By ]
In the Lightning Round, Cramer was bullish on Paychex (PAYX) , Martin Marietta Materials (MLM) and XPO Logistics (XPO) .
Cramer was bearish on 3M (MMM) , Fitbit (FIT) and Granite Construction (GVA) .
- [By Logan Wallace]
XPO Logistics (NYSE:XPO)‘s stock had its “buy” rating reissued by research analysts at Bank of America in a research note issued on Friday. They presently have a $105.00 target price on the transportation company’s stock. Bank of America’s price objective would indicate a potential upside of 4.86% from the stock’s previous close.
- [By Rich Duprey, Nicholas Rossolillo, and Maxx Chatsko]
Yet finding the best stocks to buy and hold isn't easy. So to help get you started, we asked three Foolish investors to pick a growth stock that they believe investors would be wise to buy now and hold for the long term. Read on to learn why they like SunPower (NASDAQ:SPWR), salesforce.com (NYSE:CRM), and XPO Logistics (NYSE:XPO).
- [By ]
In the Lightning Round, Cramer was bullish on Idexx Laboratories (IDXX) , XPO Logistics (XPO) , Diamondback Energy (FANG) and Illinois Tool Works (ITW) .